MaxCyteMXCT +3.54%62 FCF Margin % is -86.94% as of Mar. 2026. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, MaxCyte ranks worse than 73.5% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MaxCyte's Free Cash Flow for the
three
months ended in Mar. 2026 was $-8.39 Mil. MaxCyte's Revenue for the
three
months ended in Mar. 2026 was $9.65 Mil. Therefore, MaxCyte's FCF Margin % for the quarter that ended in Mar. 2026 was -86.94%.
The historical rank and industry rank for MaxCyte's FCF Margin % or its related term are showing as below:
MXCT'
s FCF Margin % Range Over the Past 10 Years
Min: -109.54 Med: -64.34 Max: -20.81
Current: -25.99
During the past 13 years, the highest FCF Margin % of MaxCyte was -20.81%. The lowest was -109.54%. And the median was -64.34%.
MXCT's FCF Margin % is ranked worse than 73.5% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs MXCT: -25.99
MaxCyte FCF Margin % Related Terms
MaxCyte FCF Margin % Historical Data
* Premium members only.
The historical data trend for MaxCyte's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MaxCyte's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a FCF Margin % of -86.94% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MaxCyte and its competitors. According to the industry distribution chart, MaxCyte ranks #599 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 73.5%.
Is MaxCyte's FCF Margin % too high?
MaxCyte's current FCF Margin % is -86.94%. Based on the distribution chart, MaxCyte ranks #599 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's FCF Margin % compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #599 out of 815 companies for FCF Margin %. This places MaxCyte in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MaxCyte and its competitors. MaxCyte's current FCF Margin % is -86.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.32 — trading 48.8% below its estimated fair value. The current FCF Margin % is -86.94%. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MaxCyte (MXCT), the current FCF Margin % is -86.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.32 is trading 48.8% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
FCF Margin %: -86.94%
GF Value™: $2.57 vs. price of $1.32 (48.8% below fair value)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
